Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Timothy P. Hughes; Marco Aurelio Salvino; Ong Tee Chuan; Alaa Elhaddad; Kudrat Abdulkadyrov; Jake Shortt; Hang Quach; Carolina Pavlovsky; Vernon J. Louw; Lee-Yung Shih; Anna G. Turkina; Luis Meillon; Yu Jin; Sadhvi Khanna; Darshan Dalal; Jeffrey H. Lipton

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Timothy P. Hughes, Marco Aurelio Salvino, Ong Tee Chuan, Alaa Elhaddad, Kudrat Abdulkadyrov, Jake Shortt, Hang Quach, Carolina Pavlovsky, Vernon J. Louw, Lee-Yung Shih, Anna G. Turkina, Luis Meillon, Yu Jin, Sadhvi Khanna, Darshan Dalal, Jeffrey H. Lipton

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Journal	Blood
Volume	126
Issue number	23
State	Published - 2015

Cite this

Hughes, T. P., Salvino, M. A., Chuan, O. T., Elhaddad, A., Abdulkadyrov, K., Shortt, J., Quach, H., Pavlovsky, C., Louw, V. J., Shih, L.-Y., Turkina, A. G., Meillon, L., Jin, Y., Khanna, S., Dalal, D., & Lipton, J. H. (2015). Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study. Blood, 126(23).

@article{212e6af2c25f48ef9a5d7e613146a5b1,

title = "Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study",

author = "Hughes, {Timothy P.} and Salvino, {Marco Aurelio} and Chuan, {Ong Tee} and Alaa Elhaddad and Kudrat Abdulkadyrov and Jake Shortt and Hang Quach and Carolina Pavlovsky and Louw, {Vernon J.} and Lee-Yung Shih and Turkina, {Anna G.} and Luis Meillon and Yu Jin and Sadhvi Khanna and Darshan Dalal and Lipton, {Jeffrey H.}",

year = "2015",

language = "American English",

volume = "126",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "23",

}

Hughes, TP, Salvino, MA, Chuan, OT, Elhaddad, A, Abdulkadyrov, K, Shortt, J, Quach, H, Pavlovsky, C, Louw, VJ, Shih, L-Y, Turkina, AG, Meillon, L, Jin, Y, Khanna, S, Dalal, D & Lipton, JH 2015, 'Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study', Blood, vol. 126, no. 23.

TY - JOUR

T1 - Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

AU - Hughes, Timothy P.

AU - Salvino, Marco Aurelio

AU - Chuan, Ong Tee

AU - Elhaddad, Alaa

AU - Abdulkadyrov, Kudrat

AU - Shortt, Jake

AU - Quach, Hang

AU - Pavlovsky, Carolina

AU - Louw, Vernon J.

AU - Shih, Lee-Yung

AU - Turkina, Anna G.

AU - Meillon, Luis

AU - Jin, Yu

AU - Khanna, Sadhvi

AU - Dalal, Darshan

AU - Lipton, Jeffrey H.

PY - 2015

Y1 - 2015

M3 - Journal Article

SN - 0006-4971

VL - 126

JO - Blood

JF - Blood

IS - 23

ER -